Molecular Mechanisms and Therapeutic Strategies for Immune Checkpoint Inhibitors in Breast Cancer: From Pathogenesis to Precision Medicine
Frontiers in Bioscience-Landmark · 17.06.2026 · 31 (6)
DOI: 10.31083/fbl45995 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 17.06.2026. Verfasst von Xueqing Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Second Hospital of Dalian Medical University, 116023 Dalian, Liaoning, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Breast Neoplasms, Precision Medicine. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Dalian Medical University Interdisciplinary Research Cooperation Project Team Funding, Basic Scientific Research Project of Higher Education Institutions of Liaoning Provincial Department of Education.
Abstract (Originalsprache)
The advent of immunotherapy, and particularly the development of immune checkpoint inhibitors (ICIs), has revolutionized the landscape of breast cancer treatment, especially for triple-negative breast cancer. However, some patients still do not benefit from immunotherapy. Breast cancer is inherently an immunotherapy “cold” tumor, which results in suboptimal clinical outcomes when ICIs are used as monotherapy. Identifying additional immunotherapeutic targets and drugs, along with developing novel strategies for combination therapy, is crucial for addressing the challenges posed by immunotherapy resistance and tumor immune escape driven by multiple mechanisms. For instance, the combination of the programmed cell death protein 1 inhibitor, pembrolizumab, with chemotherapy has demonstrated remarkable clinical efficacy and is now the preferred first-line treatment for neoadjuvant, adjuvant, and metastatic breast cancer. This review discusses recently developed ICIs and focuses on strategies combining ICIs with chemotherapy, targeted therapy, nanotherapy, and other approaches in breast cancer. This review aims to summarize recent advances in immune checkpoint inhibitor-based combination strategies in breast cancer and to provide insights into improving therapeutic efficacy, overcoming treatment resistance, and ultimately enhancing patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Second Hospital of Dalian Medical University, 116023 Dalian, Liaoning, China.
- Institute (College) of Integrative Medicine, Dalian Medical University, 116044 Dalian, Liaoning, China.
- Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Förderung
- National Natural Science Foundation of China
- Dalian Medical University Interdisciplinary Research Cooperation Project Team Funding
- Basic Scientific Research Project of Higher Education Institutions of Liaoning Provincial Department of Education
- Dalian Medical Science Research Program
Zitieren
APA
Wang, X., Jia, X., Zhuo, Q., Xu, C., Wang, K., & Li, M. (2026). Molecular Mechanisms and Therapeutic Strategies for Immune Checkpoint Inhibitors in Breast Cancer: From Pathogenesis to Precision Medicine. Frontiers in Bioscience-Landmark, 31(6). https://doi.org/10.31083/fbl45995
Vancouver
Wang X, Jia X, Zhuo Q, Xu C, Wang K, Li M. Molecular Mechanisms and Therapeutic Strategies for Immune Checkpoint Inhibitors in Breast Cancer: From Pathogenesis to Precision Medicine. Frontiers in Bioscience-Landmark. 2026;31(6). doi:10.31083/fbl45995
BibTeX
@article{Wang2026,
author = {Wang, Xueqing and Jia, Xiaomeng and Zhuo, Qiping and Xu, Caiming and Wang, Kainan and Li, Man},
title = {Molecular Mechanisms and Therapeutic Strategies for Immune Checkpoint Inhibitors in Breast Cancer: From Pathogenesis to Precision Medicine},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {6},
doi = {10.31083/fbl45995}
}
EUVIMED